A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-Line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL).

Trial Profile

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-Line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2015

At a glance

  • Drugs Dacetuzumab (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms MARINER
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 11 Oct 2011 Planned end date changed from 1 Feb 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Results presented at the 11th International Conference on Malignant Lymphoma (ICML).
    • 06 Oct 2009 Status changed from recruiting to discontinued as reported in a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top